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Abstract. The objective of this pilot clinical study was to 
assess the safety, technical feasibility, pharmacokinetic (PK) 
profile and tumour response of DC Bead™ with irinotecan 
(DEBIRI™) delivered by intra-arterial embolisation for the 
treatment of metastatic colorectal cancer. Eleven patients 
with unresectable liver metastases from CRC, tumour burden 
<30% of liver volume, adequate haematological, liver and 
renal function, performance status of <2 were included in 
this study. Patients received up to 4 sessions of TACE with 
DEBIRI at 3-week intervals. Feasibility of the procedure, 
safety and tumour response were assessed after each cycle. 
PK was measured after the first cycle. Patients were followed 
up to 24 weeks. Only mild to moderate adverse events were 
observed. DEBIRI is a technically feasibile procedure; no 
technical complications were observed. Average Cmax for irino-
tecan and SN-38 was 194 ng/ml and 16.7 ng/ml, respectively, 
with average t½ of 4.6 h and 12.4 h following administration of 
DEBIRI. Best overall response during the study showed disease 
control in 9 patients (2 patients with partial response and 7 with 
stable disease, overall response rate of 18%). Our study shows 
that transarterial chemoembolisation with irinotecan-loaded 
DC beads (DEBIRI) is safe, technically feasible and effective 
with a good PK profile.
Introduction
Despite the existence of excellent screening and preventive 
strategies, colorectal carcinoma remains a major public health 
problem in western countries. The American Cancer Society 
estimates there will be 142,570 new cases diagnosed in 2010 and 
51,370 people will die of the disease. In Germany, the incidence 
was about 70,404 in 2010 and 27,582 people died of colorectal 
cancer (2). Hepatic metastasis of colorectal cancer is common 
and by the time of diagnosis, 25% of colon cancers and 50%-70% 
of cancers of the rectum will have extended through the bowel 
wall metastasising to lymph nodes in 50%-60% (3). The most 
common site of extra-lymphatic involvement is the liver, with 
the lungs as the most frequently affected extra-abdominal organ. 
Patients with metastatic colorectal tumours frequently die of 
hepatic failure due to liver metastases. Therefore, treatment of 
liver metastases may prolong survival, even in the presence of 
extra-hepatic disease.
Treatment options for patients with liver metastatic 
colorectal cancer are limited and clinical outcome is generally 
poor. Surgical resection in selected patients can achieve 30-70% 
5-year survival (4-6). However, only 20-30% of patients with 
colorectal liver metastases are suitable for resection at initial 
presentation (7,8) and 70-80% of patients will develop recur-
rence within 5 years (9).
Untreated colorectal metastases to the liver have a poor 
prognosis and are associated with a median survival of 5-10 
months (10). Systemic chemotherapy can palliate symptoms 
and improve survival. 5-Fluorouracil (5-FU)-based chemo-
therapy has been the cornerstone of treatment of unresectable 
CRC for more than 40 years, and new drugs such as irinotecan, 
oxaliplatin, cetuximab and bevacizumab have recently broad-
ened the options for treatment. With the introduction of these 
novel agents, median survival has increased significantly from 
6 months to over 20 months (11).
In addition to systemic chemotherapy, current therapies 
of unresectable liver lesions include hepatic arterial infusion 
of chemotherapeutic drugs, transarterial chemoembolisation, 
radiofrequency ablation, cryotherapy, laser-induced thermo-
therapy (LITT) and yttrium-90 radioembolization (12-16).
Recent reports on the use of irinotecan loaded DC beads 
(DEBIRI) in transarterial chemoembolisation (TACE) therapy 
for metastatic colorectal cancer show promising results (17,18). 
These early reports suggest DEBIRI as a safe and effective 
treatment for patients with liver predominant unresectable 
metastases from colorectal cancer. This study was the first 
clinical evaluation in the development of DEBIRI. Critical 
features of this study relate to safety (adverse events), technical 
feasibility, PK, profile and efficacy (tumour response, time to 
progression and necrosis) which were considered pivotal in the 
assessment of DEBIRI as a therapy for unresectable metastases 
from colorectal cancer.
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Materials and methods
This prospective, pilot, single-arm study, approved by an inde-
pendent ethics committee, was conducted in our institution 
from January 2006 to April 2008. Thirty patients were planned 
to be enrolled, but the study was closed after 11 patients were 
included due to the slow recruitment rate.
Colorectal cancer stage IV (Dukes' D, TNM: TX, NX, 
M1) patients were eligible for enrolment if they gave written 
informed consent, were at least 18-year-old, of any race or 
sex, had their primary tumour(s) successfully removed by 
surgery, had 1 to 8 measurable unresectable metastase(s) 
that were confined to the liver, with a tumour burden of no 
more than 30% of liver volume. In addition, patients were 
required to have an ECOG performance status score of ≤1, 
with a life expectancy of >6 months, and adequate liver, renal 
and hematologic function. Women of child bearing potential 
and fertile men were required to use effective contraception 
and prior therapy was permitted (with or without irinotecan) 
if the last chemotherapy or prior radiotherapy treatment was 
completed at least 4 weeks before enrolment. Exclusion to 
therapy included the presence of extrahepatic metastases, 
any contraindications to irinotecan, active bacterial, viral or 
fungal infection, presence of another concurrent malignancy, 
prior malignancy in the last 5 years (except adequately treated 
basal or squamous cell skin cancer or carcinoma in situ of 
the cervix) and any contraindication for hepatic embolisation 
procedures.
All patients had baseline MRI/CT to document the extent 
of liver disease prior to therapy. Patients were to receive TACE 
treatments with DEBIRI as monotherapy every 3 weeks (up to 
4 treatments) and followed up for 6 months. Last chemotherapy 
or prior radiotherapy treatment had to be completed at least 
4 weeks before study entry (first treatment).
The primary study endpoint of safety was measured by 
adverse events, serious adverse events, and physical and labo-
ratory assessments. Secondary study endpoints of technical 
feasibility, pharmacokinetic profile (irinotecan and SN-38) 
and efficacy [tumour response and time to progression (TTP) 
measured by MRI/CT assessments according to RECIST at 
3 and 6 months following the first DEBIRI treatment] were 
also measured. Where feasible, the percentage necrosis was 
calculated as total necrotic tumour volume divided by total 
treated tumour volume.
Transarterial chemoembolisation with irinotecan loaded 
DC bead (DEBIRI). DC Bead (Biocompatibles, Farnham, 
UK) comprise a range of modified polyvinylalcohol 
hydrogel microspheres that are biocompatible, hydrophilic, 
non-resorbable, and precisely calibrated. DC Bead is a CE 
marked drug delivery embolisation system and is indicated 
for loading irinotecan (DEBIRI) for embolisation of vessels 
supplying malignant colorectal cancer metastasised to the 
liver (mCRC) and is capable of eluting a local, controlled, 
sustained dose of irinotecan to hepatic metastases of 
colorectal cancer. DC Beads of 100-300 µm and 300-500 µm 
in size were loaded with irinotecan to dose of 50 mg/ml 
beads according to the instructions for use. After removing 
saline from the vials, 5 ml of 20 mg/ml irinotecan solution 
was added to each vial of DC Bead. At the time of our study, 
vials were stored for at least 4 h for loading; however, the 
recommended loading time is 2 h. At the end of the loading 
period the supernatant was discarded and beads mixed 50:50 
with non-ionic contrast (Omnipaque
®).
All patients were adequately pre-medicated according 
to standard hospital procedure for chemoembolisation and, 
where required, included prophylactic pain management, anti-
emetics and corticoids using 100 mg Pethidin (Dolantin
®), 
3 mg Granisetron (Kevatril
®) and 20 mg Fortecortin, 10 ml 
Mepivacain (Scandicain
®) was also used for local anaesthesia 
subcutaneously. Additional pain medication and/or vasodilators 
were used at the investigator's discretion.
A diagnostic angiogram was performed to evaluate the 
hepatic aterial supply and verify portal patency. The right or 
left hepatic artery was selected, depending on the location 
of the lesions to be treated. Once the vascular supply of the 
tumour was identified, a microcatheter was placed superselec-
tively and distal to the cystic artery in close proximity to the 
lesions. Irinotecan loaded DC Bead was injected slowly until 
complete stasis of blood flow was achieved (embolisation 
endpoint). Up to 8 ml of loaded DC Bead (400 mg irinotecan) 
was to be delivered until the embolisation endpoint was 
achieved. This dose was considered safe for local delivery 
based on two preclinical studies in a porcine liver model (19) 
and is less than the recommended 3-weekly dose of irinotecan 
monotherapy (350 mg/m
2). Infusion of the beads was stopped 
if the embolisation endpoint was achieved prior to delivery 
of the full dose. No additional embolic agent was used to 
achieve the embolisation endpoint. Following the procedure 
all patients were observed for vital signs, femoral access site, 
pain management, fluid hydration and discharged according 
to standard hospital procedure.
Pharmacokinetics. Blood samples were taken prior to and at 5, 
10, 15 and 30 min, 1, 2, 4, 6 and 24 h and on day 21 after the 
first DEBIRI treatment. Plasma levels of irinotecan and SN-38 
were measured using an HPLC fluorescence method previously 
validated at CentraLabs Clinical Research (Huntington, UK). 
Peak plasma concentrations (Cmax), area under the curve (AUC) 
and plasma half-life (t½) were measured for irinotecan and its 
main active metabolite SN-38.
Statistical consideration. This was a pilot phase I/II study 
intended to assess feasibility. No well-documented ‘gold-
standard’ protocol for chemoembolisation of liver metastases 
that could serve as a control is recognised by the medical 
community. Furthermore, placebo-control in patients with 
metastatic cancer was considered unethical and ruled out. 
A single-arm, non-comparative study was thus the suitable 
design for this initial safety study. A planned enrolment 
of 30 patients was considered adequate for this assess-
ment. Descriptive and quantitative statistics were used to 
summarise categorical variables and continuous variables. 
When relevant, the 95% confidence intervals (CI) were also 
reported. Spearman rank correlation was used to determine 
any relationship between dose and adverse events. Time to 
progression was calculated using Kaplan-Meier. Paired t-tests 
and non-parametric sign tests were performed on paired data 
continuous variables. The latter was used because of the 
small sample size of this study.INTERNATIONAL JOURNAL OF ONCOLOGY  41:  1213-1220,  2012 1215
Results
Demographics. A total of 11 patients (8 males, 3 females) with 
a mean age of 64 years (range 45-85 years) were enrolled in the 
study. All patients had prior surgery to successfully remove their 
primary colorectal cancer. Eight patients had further treatment 
for their liver metastases including, laser-induced interstitial 
thermotherapy, radiofrequency ablation and radiotherapy. Mean 
sum of longest diameter in target lesions was 63±25 mm (range 
19-102 mm) with percentage liver involvement of 8.2±2.6% 
(range 4-12%). Eight patients had information on prior chemo-
therapy (Table I).
Of the 11 patients enrolled, 9 patients successfully received 
4 TACE treatments with DEBIRI. Two patients were withdrawn 
after the second DEBIRI treatment, one due to a vascular 
abnormality with shunting to the heart, the other due to intra-
hepatic progression (Fig. 1). The median follow-up period for 
all the patients was 83 days (range, 24-176 days). Three patients 
withdrew from the study due to intrahepatic progression whilst 
4 patients were considered eligible for laser-induced interstitial 
thermotherapy (LITT) following DEBIRI (Fig. 1).
Treatment. The pre-planned dose of irinotecan loaded DC Bead 
was up to 400 mg (8 ml beads) in each treatment. Final delivered 
dose varied in the patients and was dependant upon volume of 
beads delivered prior to the embolisation endpoint.
In all cases, the embolisation endpoint (stasis of the subseg-
mented artery) was achieved with less than 4 ml (200 mg 
irinotecan). In the 40 DEBIRI treatments performed, between 
21-143 mg irinotecan was delivered in each treatment session 
and an average total dose of 293 mg (range 124-440 mg) per 
patient was achieved across all their individual treatments. Bead 
size of 100-300 µm and 300-500 µm were used throughout the 
treatments.
Figure 1. CONSORT overview of study participation.
Table I. Patient demographics and tumour characteristics.
Demographics  n    %
Male/female  8/3   73/27
Caucasian/other  11/0  100/0
Age (mean ± SD, range)    64±12, 46-85
ECOG 0/1  11/0    100/0
No of lesions
  1  5    46
  2  4    36
  3  1    9
  >3  1    9
Sum of longest diameter,
mm (mean ± SD, range)    63±25, 19-102
Liver involvement,
% (mean ± SD, range)    8.2±2.6, 4-12
Prior  chemotherapy  (data  from  8  patients):  FOLFOX  6;  5-FU 
(2  cycles),  oral  Xeloda;  CAPOX  +  FOLFOX,  oxaliplatin/Tomudex, 
Tomudex monotherapy; 5-FU. No previous chemotherapy (3 patients): 
FOLFOX (6 cycles); FOLFOX (5 cycles); FOLFIRI (6 cycles), folinic 
acid + 5-FU + irinotecan + Avastin.EICHLER et al:  INTRAARTERIAL THERAPY WITH BEADS 1216
Safety. Ten patients retained an ECOG status of ≤1 during the 
study. Nine of the 11 patients (81.8%) experienced a total of 41 
adverse events during the study. Each adverse event (AE) was 
coded according Medical Dictionary for Regulatory Activities, 
MedDRA version 10.0 (MSSO 2007) (Table II). Gastrointestinal 
disorders were the most common AEs (63%) predominantly due 
to abdominal pain, nausea and vomiting. These are consistent 
with the expected post-embolisation syndrome observed in 
patients undergoing chemo-embolisation of the liver. The 
majority of AEs were mild (61%) with the remainder graded as 
moderate (39%). No irinotecan related toxicities such as delayed 
diarrhoea or neutropenia were observed.
No serious adverse events (SAEs) were reported during the 
study and no clinically significant changes from baseline values 
were observed in the laboratory findings. The Spearman's rank 
correlation coefficient was calculated to examine whether an 
association existed between dose delivered and number of 
adverse events. The coefficients (rs =0.289 and 0.187 for total 
dose and mean dose, respectively) showed no evidence of an 
association between dose and total number of adverse events 
experienced.
Technical feasibility. Forty DEBIRI treatments were success-
fully performed in these 11 patients. No technical complications 
were reported during the study demonstrating feasibility of 
DEBIRI in the treatment of patients with liver metastases from 
colorectal cancer.
Pharmacokinetics (PK). PK analyses were completed for 
10 patients. Average dose of irinotecan delivered in PK patients 
Table II. Adverse events.
System organ class  Preferred term  Events    Patients
Cardiac  disorders  Total  1 2.4%  1 9.1%
    Palpitations  1  2.4%  1  9.1%
Gastrointestinal  disorders  Total  26 63.4%  9 81.8%
    Abdominal discomfort  2  4.9%  1  9.1%
    Abdominal pain  6  14.6%  5  45.5%
    Constipation  1  2.4%  1  9.1%
    Nausea  9  22.0%  6  54.5%
      Vomiting  8 19.5%  7 63.6%
General disorders and  Total  3  7.3%  3  27.3%
administration site conditions    Asthenia  1  2.4%  1  9.1%
    Pain  2  4.9%  2  18.1%
Infections and infestations  Total  1  2.4%  1  9.1%
    Device related infection  1  2.4%  1  9.1%
Investigations  Total  7 17.1%  2 18.1%
    Blood pressure increased  4  9.8%  1  9.1%
    White blood cell count increased  3  7.3%  1  9.1%
Musculoskeletal  and  Total  1 2.4%  1 9.1%
connective tissue disorders    Musculoskeletal chest pain  1  2.4%  1  9.1%
Respiratory, thoracic and  Total  2  4.9%  2  18.1%
mediastinal disorders    Dyspnoea  2  4.9%  2  18.1%
Total    41   11
Table III. Average pharmacokinetic parameters for irinotecan and SN-38.
 Cmax Tmax AUCt AUC24 AUC  λz t1/2
  (ng/ml)  (h)  (ng•h/ml)  (ng•h/ml)  (ng•h/ml)  (1/h)  (h)
Irinotecan
  Mean  194  2a  1,510 1,520 1,680  0.1502  4.6b
  SD  124    1,050  1,040  1,200  0.1346
SN-38
  Mean  16.7  1a  147 147 281  0.0559  12.4b
  SD  11.3    99  99  352  0.0238
aValue is the median; 
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was 86 mg. Peak plasma concentrations (Cmax), area under the 
curve (AUC) and plasma half-life (t½) results for irinotecan and 
its main active metabolite SN-38 are shown in Table III. Cmax for 
irinotecan and SN-38 were 194 ng/ml and 16.7 ng/ml, respec-
tively, following administration of DEBIRI. Average AUC values 
were 1,680 ng•h/ml and 281 ng•h/ml, respectively. t½ ranged 
from 1.6-7.2 h (mean 4.6 h) for irinotecan and 7.6-8.5 h (mean 
12.4 h) for SN-38. Results for AUC and t½ should be treated with 
caution as data from the majority of patients did not meet the 
data acceptance criteria to calculate the slope of λz requiring a 
minimum of 3 terminal data points randomly distributed on a 
straight line with a regression coefficient of ≥0.95, the fraction 
of the variance accounted for was ≥0.90 and an interval at least 
2-fold greater than t½.
Efficacy. Tumour response was assessed according to Response 
Evaluation Criteria in Solid Tumours (RECIST) (20). Up to 5 
target lesions in the liver were followed and the sum of longest 
diameters used to assess tumour response. Stable disease was 
reported in 9 (81%) of patients after the first DEBIRI treatment 
and 7 (64%) remained stable by the third treatment (week 9) 
with one achieving partial response (Fig. 2).
By the end of the study, intrahepatic progression of the 
disease according to RECIST was reported in 7 patients (63%), 
a partial response to treatment in 2 patients (18%) and stable 
disease reported in 2 patients (18%) (Table IV). These four 
patients received the LITT treatment in the follow-up. Best 
overall response was defined as the best response from start 
of treatment over all follow up visits or until disease progres-
sion/recurrence. Best overall response during the study showed 
disease control in 9 patients (2 patients with partial response and 
7 with stable disease).
It was planned to measure the extent of tumour necrosis 
following DEBIRI, however, we found that tumour necrosis was 
difficult to assess and only possible in 3 patients. No conclusions 
could be drawn from this assessment.
Tumour markers. Carcinoembryonic antigen (CEA) and 
cancer/carbohydrate antigen 19-9 (CA 19-9) (21) were measured 
pre- and post-DEBIRI treatment. Nine (82%) patients had 
clinically significant levels of CEA at baseline that remained 
throughout the study. Three patients (27%) saw an average 
decrease of 71% (range 61 to 79%) in their CEA levels. When 
compared to overall treatment outcome (RECIST), an increase 
Figure 2. Fifty-four-year-old patient with a liver metastases in liver segment eight. After the first treatment devascularisation and necrosis in the lesion is observed, 
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in CEA level from baseline to last measurement was associated 
with disease progression in 6 of the 7 (86%) patients. In the 
3 patients with a decrease in CEA level compared to baseline 
values, a stable disease or partial responses was observed. A 
similar trend was also found in the CA 19-9 results.
Time to progression (TTP). Probability of disease progression 
was determined using the Kaplan-Meier method. Based on 
responses assessed at the treatment and follow-up visits, median 
TTP from first treatment was 154 days (95% CI, 17-291 days) 
(Fig. 3).
Discussion
The management of metastatic colorectal cancer is becoming 
far more complex and requires a multidisciplinary and collab-
orative approach in selecting the optimal treatment for patients 
with liver metastases of colorectal cancer. Despite advances in 
the development of new cytotoxics and targeted biologics for the 
treatment of hepatic metastases from colorectal cancer, there is 
still interest in liver directed, locoregional therapy to improve 
treatment response and potentially improve survival. Prognosis 
in these patients remains poor with 1- and 3-year median 
survival rates of 31% and 2% (5,22-24). With response rates 
in second-line systemic chemotherapeutic treatments between 
4-22%, a more precise chemotherapeutic delivery system to 
maximize response rates and reduce side effects is a potential 
option in the treatment algorithm for hepatic metastases from 
colorectal cancer (25).
Transarterial chemoembolisation (TACE) is a locoregional 
therapy that is most widely used for the treatment of unresect-
able HCC (26-28) and involves the periodic injection of a 
chemotherapeutic agent, mixed with an embolic material, into 
selected branches of the hepatic arteries feeding a liver tumour. 
The expected advantage of TACE is that higher concentrations 
of the drug can be delivered to the tumour with decreased 
systemic exposure compared with systemic chemotherapy. 
We have learnt from hepatic artery infusion (HAI), that even 
tumours unresponsive to systemic therapy may benefit from the 
higher doses afforded by local delivery (29).
Early reports on the use of conventional TACE in the 
treatment of hepatic metastases from colorectal cancer were 
encouraging (30) and data from several reports have now 
emerged on effectiveness, response rates, side effects and overall 
survival. One of the largest series published evaluated the effi-
cacy of TACE with respect to local control and survival (31). 
Patients (n=463) with liver metastases from colorectal cancer 
were treated with repeated TACE at 4-week intervals. In total, 
2,441 chemoembolisations were performed with a mean of 5.3 
sessions per patient. The chemotherapy consisted of mitomycin 
C with/without gemcitabin or mitomycin C with irinotecan 
and embolisation was performed with lipiodol and starch 
microspheres for vessel occlusion. Tumour response according 
to RECIST 3 months after the three TACE administrations 
was evaluated by MRI. Partial response was observed in 12% 
of patients, stable disease in 51% and progressive disease in 
37%. The 1-year survival rate was 62%, but dropped to 38% by 
2 years. Median survival time from first TACE treatment was 
1.34 years (31).
In recent decades, many efforts have been made to improve 
the outcome of TACE by integrating new chemotherapeutic 
Table IV. Tumour response according to RECIST.
Patient  Post-treatment 1  Post-treatment 2  Post-treatment 3  Post-treatment 4  Follow-up
  (week 3)  (week 6)  (week 9)  (week 12)  (week 24)
001  Stable  Stable  Stable Progression -
002  Stable Stable Stable Stable  Progression
003 Stable  Stable Progression  -  -
004  Stable Stable Stable Stable -
005  Stable Stable Stable Stable  Progression
006  Stable  Stable  Partial response  Partial response  -
007  Progression Progression  -  -  -
008  Stable Stable Stable Stable -
009  Stable Stable Stable Stable  Progression
010  Stable  Stable  Stable  Partial response  -
011 Progression  -  -  -  -
Figure 3. Probability of progression according to RECIST.INTERNATIONAL JOURNAL OF ONCOLOGY  41:  1213-1220,  2012 1219
agents and providing a more accurate dosage of drug delivery 
to the liver for a more prolonged period. DC Bead is capable 
of loading irinotecan and release the drug in a sustained way 
in the liver after injection in the hepatic artery. Fiorentini 
et al (17) evaluated irinotecan loaded DC Beads (DEBIRI) in 
20 patients with liver metastases from colorectal cancer in a 
palliative setting. A relevant response was observed in 16 out 
of 20 patients, with significant reduction of lesional contrast 
enhancement in all responding patients. The procedure was 
well tolerated by most patients with a median duration of 
hospitalization of 3 days (range 1-10 days). The most important 
adverse effect was abdominal pain, especially during injection 
of irinotecan loaded DC beads.
A randomised, phase III study (1), compared DEBIRI vs 
FOLFIRI in patients who failed 2/3 lines of systemic chemo-
therapy. At a median follow-up of 24 months, median overall 
survival was improved by 43% in the DEBIRI arm (690 days) 
compared with the FOLFIRI arm (482 days) with significantly 
better response and PFS in favour of DEBIRI (68%, 225 days 
vs 18%, 94 days, respectively). Acute toxicity (G3 pain, nausea, 
fever) was greater with DEBIRI and was observed in the context 
of post-embolisation syndrome, and were controlled with 
intravenous hydration, morphine and antibiotics. Late toxicity 
was significantly higher with FOLFIRI. Diarrhoea, asthenia, 
leucopenia, anaemia and G3 fever were substantially less with 
DEBIRI (2-20% vs 35-50%). This is the first study to report a 
clear survival benefit of DEBIRI over systemic chemotherapy 
with a reduction in overall cost. Martin et al published data 
from an open-label multi-center study where 55 patients with 
unresectable liver metastases from CRC underwent 99 DEBIRI 
treatments (32). Median length of hospital stay was 24 h. Median 
disease-free and overall survival from the time of first treatment 
was 247 days and 343 days, respectively. Six patients (10%) were 
downstaged from their original disease status.
In our pilot study, 11 patients with up to 8 hepatic lesions 
from CRC were treated with DEBIRI. This was the first clinical 
evaluation in the development of DEBIRI and aimed to evaluate 
the safety, technical feasibility, PK profile and efficacy of this 
new treatment.
The treatment showed an excellent safety profile with no 
serious adverse events reported. No clinically significant change 
in blood biochemistry or dose limiting toxicity for irinotecan 
was observed. These results are of interest since anaemia has 
been reported in approximately 58.7% of patients receiving 
intravenous irinotecan monotherapy at the recommended dose 
and neutropenia and delayed diarrhoea are known to cause 
dose-limiting toxicity (33). These results confirm reports by 
Fiorentini et al (17) and Martin et al (32).
We report a relatively high incidence of post-procedural pain 
which is expected following hepatic arterial injection of irino-
tecan. Use of intravenous opioids and intra-arterial injection of 
1% lidocaine has now become standard in the pain management 
protocols of patients undergoing DEBIRI treatment.
TACE is well established in the treatment algorithm for 
hepatocellular carcinoma and is becoming more accepted in the 
treatment of liver metastases from colorectal cancer. DEBIRI 
was found to be technically feasible in our study and since that 
time has gained increasing evidence as a viable treatment option 
for these patients. With respect to PK, average Cmax, AUC and t½ 
results for irinotecan in this study were 194 ng/ml, 1,680 ng•h/ml 
and 4.6 h, respectively. These results are considerably lower than 
reported values following i.v. administration of irinotecan (34) 
demonstrating the low bioavailability following DEBIRI treat-
ment. In contrast, higher than expected levels of the main active 
metabolite SN-38 was observed. Average Cmax, AUC and t½ for 
SN-38 were 16.7 ng/ml, 281 ng•h/ml and 12.4 h, respectively. 
It is too early to conclude whether DEBIRI has any potential 
to increase the availability of SN-38 and further research is 
required to confirm this hypothesis.
Response rates in the current study showed stabilisation of 
the disease in 64% and a partial response in 18% of patients 
at 9 weeks after the first treatment. These response rates are 
in line with those reported in the second-line (refractory to 
5-fluorouracil) phase II studies that formed the basis of approval 
for irinotecan monotherapy where response rates of 13.3-21.7% 
were achieved (35), however 9 weeks is a relatively short follow-
up in this study and longer term data has now been published 
on the efficacy of DEBIRI. The time to progression of 154 days 
was shorter than previously reported but may reflect the patient 
population in which many had prior treatments for their 
colorectal disease. Following DEBIRI treatment, four patients 
were found to be eligible for laser-induced thermotherapy with 
the potential for better prognosis.
Our results for safety are consistent with recent publications 
on DEBIRI, but our efficacy results differ from recent reports. As 
this was the first clinical study of DEBIRI in mCRC we adopted 
the same technical approach for TACE in the treatment of 
hepatocellular carcinoma using a superselective stasis endpoint. 
Liver metastases from colorectal cancer are generally more 
hypovascular than HCC and may explain the lower than planned 
volume of DEBIRI delivered during the study. Since the time of 
our study, more experience has been gained on the optimised 
technique to use with DEBIRI. For patients with enough liver 
preserve, a more proximal catheter position and a lobar approach 
is now recommended to ensure delivery of DEBIRI to entire 
tumour area. The catheter should be positioned in lobar arteries 
past any extrahepatic vessel (e.g. cystic, pancreatic, gastro-
duodenal arteries). From there DEBIRI should be injected slowly 
(~1 ml/min) until an endpoint of stasis in the intratumoral vessels 
whilst maintaining flow in the afferent vessels is achieved. It is 
not recommended to achieve stasis up to the catheter position. 
Our superselective approach with stasis endpoint may have 
missed some non-visible lesions causing them to be undertreated. 
This may explain the differences in efficacy results reported in 
our study compared to more recent publications.
Results from the present study are encouraging but are limited 
due to the small sample size and the relatively short follow-up. 
We demonstrated that DEBIRI therapy is a safe alternative treat-
ment in the management of patients with hepatic metastases from 
colorectal cancer with an optimised pharmacokinetic profile as 
compared to systemic chemotherapy. Patients tolerated the treat-
ment well at the doses and schedules used in this study which 
could allow this therapy to be considered in combination with 
systemic chemotherapy including irinotecan, oxaliplatin, as well 
as bevacizumab and cetuximab and other new biologic agents.
RECIST is a well established criteria for tumour response 
assessment in oncology trials, however, it is not appropriate for 
locoregional treatments such as DEBIRI. Assessment of tumour 
viability and tumour necrosis such as the mRECIST criteria in 
HCC (36) may provide a better assessment of treatment response. EICHLER et al:  INTRAARTERIAL THERAPY WITH BEADS 1220
In our patients we were unable to measure tumour necrosis 
accurately. In addition, our technical approach was different to 
that reported in more recent publications and may explain the 
higher rate of progressions seen in our study. We are now partici-
pating in a German, multicentre, randomised study of DEBIRI + 
cetuximab (DEBIRITUX) vs irinotecan + cetuximab using the 
recommended DEBIRI technique (proximal approach) to assess 
progression-free survival of this combined treatment.
In conclusion, our study shows that chemoembolisation 
with irinotecan loaded DC Beads (DEBIRI) is safe, technically 
feasible and effective with a good PK profile. These positive 
and promising results have now been further investigated and 
confirmed in a larger patient population. Studies are underway to 
investigate this technology in all lines of therapy and in combina-
tion with existing systemic treatments for liver dominant disease 
from colorectal cancer.
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